Kazia Therapeutics Ltd.
13F holders, Q1 2025 (March 31)10holders −1
2new positions
3sold out
$0.78avg. 13F price*
At the end of Q1 2025, 10 institutions reported holding Kazia Therapeutics Ltd. in their 13F filings, down 1 from Q4 2024. 2 opened new positions and 3 sold out. The largest holders were Barclays PLC ($94K), UBS Group AG ($21K) and MAI Capital Management ($3K).
- Company
- Kazia Therapeutics Ltd.
- CUSIP
- 48669G204
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $2K |
| Exits | 3 | $56K |
All 13F filers, Q4 2024 → Q1 2025: 2,329 shares bought and 169,561 shares sold, net −167,232 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Barclays PLC | 0.00% | No change | 120,000 | $94K |
| UBS Group AG | 0.00% | Reduce -4.6% | 26,285 | $21K |
| MAI Capital Management | 0.00% | Reduce -97.2% | 3,854 | $3K |
| Rhumbline Advisers | 0.00% | Reduce -31.2% | 1,911 | $1K |
| GAMMA Investing LLC | 0.00% | New | 1,327 | $1K |
| Arax Advisory Partners | 0.00% | New | 1,000 | $783 |
| Osaic Holdings, Inc. | 0.00% | No change | 50 | $39 |
| Allworth Financial LP | 0.00% | Reduce -87.5% | 1 | $4 |
| Wells Fargo & Company | 0.00% | Add +100.0% | 4 | $3 |
| Simplex Trading, LLC | 0.00% | Reduce -99.3% | 5 | $0 |
"% of holder's portfolio" is KAZIA THERAPEUTICS LTD's weight in each manager's 13F, not the share of Kazia Therapeutics Ltd. the manager owns.